Background
==========

Alzheimer\'s disease (AD) is accompanied by a chronic inflammatory process, including activation of microglia and astrocytes that express pro-inflammatory cytokines \[[@B1],[@B2]\]. It is unclear to what extent this inflammation is a reaction to the pathology of AD, and to what extent it contributes to the onset or progression of the disease.

Two multi-functional cytokines, interleukin-6 (IL-6) and interleukin-10 (IL-10), may be relevant to this question. IL-6 is a potent pro-inflammatory cytokine \[[@B3]\], while IL-10 acts to limit inflammation in the brain \[[@B4]\]. Both are produced by activated microglia and astrocytes \[[@B3],[@B4]\]. Two single nucleotide polymorphisms (SNPs), rs1800795 (-174G/C) and rs1800896 (-1082G/A), in the regulatory regions of the genes, *IL6*and *IL10*, respectively, have been widely studied. However, the ongoing AlzGene meta-analyses of the two SNPs \[[@B5]\]<http://www.alzforum.org/res/com/gen/alzgene/> are both currently negative (4 July 2009): pooled odds ratios for Caucasians in single-locus analyses of *IL6*-174C versus G alleles = 0.93 (95% confidence interval: 0.79--1.08, 14 studies) and of *IL10*-1082G versus A alleles = 0.91 (0.74--1.11, eight studies). Our own meta-analyses, both by allele and by genotype, confirmed these results and also indicated a high degree of heterogeneity among the studies (*p*\< 0.05 in seven out of eight analyses, data not shown). Such inconsistencies may be due to study differences, e.g. in design or technical or analytical approach. However, the heterogeneity remained in six out of eight analyses after altogether four studies with controls in Hardy-Weinberg disequilibrium were removed. Alternatively, the heterogeneity may reflect true population differences, such as in interactions with other factors, including other genes. Such diverse results have been described as a marker of epistasis \[[@B6],[@B7]\], i.e. where the effect of one polymorphism depends on the genotype at another locus.

Infante et al (2004) \[[@B8]\] reported an interaction between *IL6*-174G/C and *IL10*-1082G/A associated with the risk of AD. We therefore set out to replicate this result in the Epistasis Project.

The Epistasis Project
---------------------

Sporadic Alzheimer\'s disease (AD) is a complex disease, with over 50% heritability \[[@B9]\]. This suggests that its study requires the investigation of interactions between risk factors, particularly genetic factors. The Epistasis Project studies such interactions, mainly those between distinct genetic loci, i.e. epistasis. The project is a collaboration of seven AD research groups: Bonn, Bristol, Nottingham, OPTIMA, Oviedo, Rotterdam and Santander (Table [1](#T1){ref-type="table"}). The project aims: first, to replicate genetic interactions that have been reported to affect the risk of sporadic AD; second, to explore other polymorphisms in the relevant genetic regions, ultimately to reveal the true risk loci. The overriding object is to gain insights into AD causality. However, interactions can only be reliably studied with sufficient statistical power and careful study design. The project therefore has these characteristics:-

###### 

Sample-sets used in the Epistasis Project

  Group        Geographical Region\*                 Subjects^†^         Numbers   \% women   *p*(AD vs controls)   Median age^‡^(interquartile range)   *p*(AD vs controls)
  ------------ ------------------------------------- ------------------- --------- ---------- --------------------- ------------------------------------ ---------------------
  Bonn         Bonn and Mainz, Germany               Clinical AD         259       61.4                             71.0 (65.1--77.5)                    
                                                     Screened controls   232       56.9       0.31                  67.8 (64.4--76.1)                    0.11
  Bristol      South-West England                    Autopsy AD          200       45.0                             80.4 (75.6--86.0)                    
                                                     Autopsy controls    57        40.4       0.55                  77.9 (72.8--82.9)                    0.12
  Nottingham   Cambridge, England                    Autopsy AD          104       48.1                             78.7 (70.8--84.6)                    
                                                     Autopsy controls    107       34.6       0.051                 72.5 (65.6--80.0)                    \< 0.001
  OPTIMA       Oxford, England                       Autopsy AD          163       54.6                             79.5 (72.4--85.2)                    
                                                     Clinical AD         87        54.0                             79.1 (73.4--84.8)                    
                                                     Screened controls   261       53.6       0.93                  78.9 (72.9--83.8)                    0.54
  Oviedo       Asturias, Spain                       Clinical AD         202       69.8                             78.4 (74.8--82.8)                    
                                                     Screened controls   131       61.8       0.15                  69.7 (63.5--74.5)                    \< 0.001
  Rotterdam    Rotterdam (Ommord), the Netherlands   Clinical AD         391       74.9                             86.6 (82.2--91.6)                    
                                                     Screened controls   5,111     57.7       \< 0.001              76.9 (71.7--83.0)                    \< 0.001
  Santander    Cantabria, Spain                      Clinical AD         351       65.0                             75.5 (70.8--78.9)                    
                                                     Screened controls   396       68.9       0.27                  80.9 (74.7--85.6)                    \< 0.001
                                                                                                                                                         
  Totals                                             Total AD            1,757     62.4                             79.0 (73.0--85.2)                    
                                                     Total controls      6,295     57.7                             76.9 (71.3--83.0)                    

AD = Alzheimer\'s disease

\*from which the samples were drawn.

^†^Clinical AD cases were diagnosed as \"probable AD\" by NINCDS-ADRDA criteria \[[@B12]\]; autopsy AD cases were diagnosed as \"definite\" or \"probable\" by CERAD criteria \[[@B11]\]; screened controls were free of cognitive impairment; autopsy controls were free of pathology consistent with AD or other dementias; all controls were ≥ 60 years of age.

^‡^Age at death or last examination.

### 1. Power

The project has 1,757 cases of AD and 6,295 elderly controls. These numbers give 99.9% power to detect an *SF*\[[@B10]\] of 2 between two polymorphisms, each with a minor allele frequency of 20%, when controlling for individual centres (2 below). They give 89.8% power or 48.6% power to detect *SF*s of 1.5 or 1.25, respectively. Quality control of genotyping reduces the numbers somewhat, depending on the polymorphism.

### 2. Selection of sample-sets

Only sample-sets drawn from narrow geographical regions with relatively homogeneous, Caucasian populations have been chosen, from seven AD research centres (Table [1](#T1){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}).

### 3. Sample characterisation

Cases of AD are either confirmed at autopsy as \"definite\" or \"probable\" by CERAD criteria \[[@B11]\], or clinically diagnosed as \"probable AD\" by NINCDS-ADRDA criteria \[[@B12]\]. Controls are either screened as free of cognitive impairment, or confirmed at autopsy as free of pathology consistent with AD or other dementias.

### 4. Matching of cases and controls

Only cases and controls drawn from the same region are compared, thus controlling for geographical differences, e.g. between North and South Europe.

### 5. Candidate interactions

Interactions are studied that have prior evidence of an association with AD and a plausible biological hypothesis. Interactions with age (± 75 years), gender and apolipoprotein E ε4 (*APOE*ε4) genotype are also examined.

### 6. Analytical methods

Logistic regression and *SF*\[[@B10]\] analyses are used. All analyses are controlled for age, gender and *APOE*ε4 genotype. All pooled analyses are also controlled for centre. There is thus no question of controls from one centre (e.g., Rotterdam) being compared with AD cases from another region. Controlling for centre also reduces the relative influence of large subgroups, such as Rotterdam controls, in the pooled result. Where pooled analyses yield significant results, the seven individual centres are also examined for associations with AD, for heterogeneity, and for power to detect the interaction.

Table [1](#T1){ref-type="table"} gives the basic characteristics of the seven sample-sets. See Additional file [1](#S1){ref-type="supplementary-material"} for further information.

To select the interactions for study, a survey of over 100 published claims and suggestions of epistasis in sporadic AD was undertaken \[[@B13]\]. The interactions finally chosen are involved in various networks that are widely considered to contribute to the development of AD: lipid metabolism \[[@B14]\], β-amyloid metabolism \[[@B15]\], oxidative stress \[[@B16]\], inflammation \[[@B1]\], insulin metabolism \[[@B17]\] and homocysteine metabolism \[[@B18]\]. Positive results should therefore deliver insights into the causes of AD.

Methods
=======

Basic information on the 1,757 cases of AD and the 6,295 controls from the seven centres is given above and in Table [1](#T1){ref-type="table"}, and fuller details are provided in Additional file [1](#S1){ref-type="supplementary-material"}.

Genotyping for the six centres other than Rotterdam was performed at the Wellcome Trust Sanger Institute, using the iPLEX Gold assay (Sequenom Inc.). Whole genome amplified DNA was used for 82% of samples; genomic DNA was used for the 18% of samples that were not suitable for whole genome amplification. A Sequenom iPLEX, designed for quality control purposes, was used to assess genotype concordance between genomic and whole genome amplified DNA for 168 individuals. Assays for all SNPs were designed using the eXTEND suite and MassARRAY Assay Design software version 3.1 (Sequenom Inc.). Samples were amplified in multiplexed PCR reactions before allele specific extension. Allelic discrimination was obtained by analysis with a MassARRAY Analyzer Compact mass spectrometer. Genotypes were automatically assigned and manually confirmed using MassArray TyperAnalyzer software version 4.0 (Sequenom Inc.). Gender markers were included in all iPLEX assays as a quality control metric for confirmation of plate/sample identity. Genotyping of SNPs rs1800871, rs2069837 and rs3024505 was carried out using the KASPar technology by KBioscience <http://www.kbioscience.co.uk>.

Genotyping in the Rotterdam cohort was done on Version 3 Illumina-Infinium-II HumanHap550 SNP array (Illumina, San Diego, USA) and additionally, SNPs were imputed using MACH software <http://www.sph.umich.edu/csg/abecasis/MACH/> with HapMap CEU Release 22 as a reference \[[@B19]\]. The reliability of imputation was estimated for each imputed SNP with the ratio of expected and observed dosage variance (O/E ratio). Only samples with high-quality extracted DNA were genotyped; 5974 were available with good quality genotyping data; 5502 of these had reliable phenotypes. For the Epistasis Project, 52 genotyped SNPs and 116 imputed SNPs were selected.

We assessed associations with logistic regression models and *SF*analysis \[[@B10]\], controlling for age, gender, *APOE*ε4 and study centre, using R Version 2.6.1 (R Foundation for Statistical Computing, Vienna, Austria). Heterogeneity between centres was controlled by fitting a fixed effect corresponding to contrasts between the baseline centre and the six other centres (having compared models with fixed- and random-effect terms in centre, goodness of fit was measured using Akaike\'s Information Criterion, which favoured using fixed effects only). Where the overall *SF*was significant at p \< 0.05, the seven individual centres and the two geographical regions, North Europe and North Spain, were also examined. Power calculations were by *SF*analysis. Meta-analyses were performed using the random-effect method of DerSimonian and Laird \[[@B20]\] and the heterogeneity test of Armitage \[[@B21]\]. Comparisons of allelic frequencies between North Spain and North Europe were by Fisher\'s exact test. We compared the medians of the age distributions of AD and control groups using the Wilcoxon-Mann-Whitney test. Linkage disequilibrium data were estimated using the R genetics library <http://cran.r-project.org/web/packages/genetics/index.html>. All tests of significance were two-sided.

Results
=======

We replicated the interaction reported by Infante et al (2004) \[[@B8]\] between *IL6*rs1800795 (-174G/C) and *IL10*rs1800896 (-1082G/A) (below). In the Rotterdam cohort, we examined altogether five *IL6*-related SNPs, rs1800797, rs1800795, rs2069837, rs2069840 and rs2069845, and four *IL10*-related SNPs, rs1800896, rs1800871, rs3024498 and rs3024505. In that preliminary study, we found that the strongest interactions were seen between *IL6*rs2069837 (intron 2 A/G) and *IL10*rs1800871 (-819C/T) and between *IL6*rs2069837 and *IL10*rs3024505 (3\' C/T) (data not shown). We therefore studied the five SNPs shown in Table [2](#T2){ref-type="table"} in all seven sample-sets.

###### 

Studied SNPs

  Gene     SNP                        Minor allele frequency in controls   LD in controls                                   
  -------- ----------- -------------- ------------------------------------ ---------------- ----------- ----------- ------- -------
  *IL6*    rs1800795   -174G/C        41.1% (C)                            32.8% (C)        \< 0.0001   rs2069837   0.998   0.055
           rs2069837   Intron 2 A/G   7.3% (G)                             9.3% (G)         0.03                            
                                                                                                                            
  *IL10*   rs1800896   -1082G/A       50.7% (G)                            43.1% (G)        \< 0.0001   rs1800871   0.999   0.296
                                                                                                        rs3024505   0.988   0.191
           rs1800871   -819C/T        22.5% (T)                            26.7% (T)        0.002       rs3024505   0.999   0.058
           rs3024505   3\' C/T        16.6% (T)                            14.2% (T)        0.06                            

SNP = single nucleotide polymorphism; LD = linkage disequilibrium; D\' = ratio of observed LD to maximum possible LD; r = correlation coefficient; *IL6*and *IL10*= the genes for interleukin-6 and interleukin-10, respectively.

Hardy-Weinberg analysis was performed for the five SNPs of Table [2](#T2){ref-type="table"} in both cases and controls of the Rotterdam samples, genotyped by Rotterdam, and of the samples from the other six centres, genotyped by the Sanger Institute. As expected by chance, one of these 20 analyses resulted in disequilibrium: *IL6*-174G/C in AD cases of the six centres (*p*= 0.02). The two *IL6*SNPs were in linkage disequilibrium (LD), as were the three *IL10*SNPs (Table [2](#T2){ref-type="table"}). The allelic frequencies differed significantly between North Europe (Bonn, Bristol, Nottingham, OPTIMA and Rotterdam) and North Spain (Oviedo and Santander) in four out of the five SNPs (Table [2](#T2){ref-type="table"}).

We examined the potential associations with AD of the six interactions generated between the two *IL6*SNPs and the three *IL10*SNPs in our overall dataset (Table [3](#T3){ref-type="table"}), controlling for centre, age, gender and *APOE*ε4 genotype (as in all association analyses). Three of the six interactions were associated with AD: *SF p*\< 0.05. The first interaction shown in Table [3](#T3){ref-type="table"} is effectively identical to that reported by Infante et al 2004 \[[@B8]\]; we have merely reversed the first genotype, i.e. CC rather than GC + GG, to give an *SF*of 1.56, rather than its inverse, 0.64, for easier comparison with the other interactions. The two *IL6*genotypes shown in Table [3](#T3){ref-type="table"} were in LD (*p*\< 0.0001), as were the three *IL10*genotypes (*p*\< 0.0001). The interaction between *IL6*intron 2 AA and *IL10*-819CC was slightly the strongest: *SF*= 1.63 (95% confidence interval = 1.10--2.41, *p*= 0.01). All further analysis was therefore restricted to that interaction.

###### 

Potential interactions between *IL6*SNPs and *IL10*SNPs in the risk of AD

  ------------------------------------------------------------------------------
  Interaction                     Numbers          Adjusted\*\
                                                   synergy factor(95% CI, *p*)
  -------------- ---------------- --------- ------ -----------------------------
  rs1800795 CC   × rs1800896 G+   6153      1557   **1.56 (1.02--2.38, 0.04)**

  rs1800795 CC   × rs1800871 CC   6158      1514   1.25 (0.86--1.80, 0.25)

  rs1800795 CC   × rs3024505 T+   6190      1546   1.11 (0.75--1.64, 0.60)

  rs2069837 AA   × rs1800896 G+   6126      1437   1.37 (0.89--2.11, 0.16)

  rs2069837 AA   × rs1800871 CC   6150      1442   **1.63 (1.10--2.41, 0.01)**

  rs2069837 AA   × rs3024505 T+   6172      1429   **1.55 (1.02--2.36, 0.04)**
  ------------------------------------------------------------------------------

*IL6*and *IL10*= the genes for interleukin-6 and interleukin-10, respectively; SNPs = single nucleotide polymorphisms; AD = Alzheimer\'s disease; CI = confidence interval; G+ and T+ group the genotypes, GA+GG and CT+TT, respectively; *APOE*ε4 = apolipoprotein E ε4.

\*All analyses controlled for centre, age, gender and *APOE*ε4 genotype.

Table [4](#T4){ref-type="table"} shows the effect of each of the two factors in that interaction on the association with AD of the other factor. The presence of *IL10*-819CC changed the association of *IL6*intron 2 AA with AD from negative (odds ratio = 0.86, *p*= 0.30) to risk (odds ratio = 1.38, *p*= 0.02), while the presence of the latter removed the protective association of the former (odds ratio = 0.63, *p*= 0.01, changed to 1.08, *p*= 0.32).

###### 

Odds ratios of Alzheimer\'s disease for two *IL6*and *IL10*SNPs, stratified by each other

  Odds ratio of AD for :-   In the subset :-   Numbers              Adjusted\* odds ratio of AD (95% CI, *p*)
  ------------------------- ------------------ ---------- --------- -------------------------------------------
  *IL6*                     *IL10*             AA: 2158   AA: 518   0.86 (0.64--1.15, 0.30)
  rs2069837                 rs1800871 T+       G+: 348    G+: 87    
  AA vs G+                  *IL10*             AA: 3099   AA: 724   **1.38 (1.06--1.79, 0.02)**
                            rs1800871 CC       G+: 545    G+: 113   
                                                                    
  *IL10*                    *IL6*              CC: 545    CC: 113   **0.63 (0.44--0.91, 0.01)**
  rs1800871                 rs2069837 G+       T+: 348    T+: 87    
  CC vs T+                  *IL6*              CC: 3099   CC: 724   1.08 (0.93--1.25, 0.32)
                            rs2069837 AA       T+: 2158   T+: 518   

*IL6*and *IL10*= the genes for interleukin-6 and interleukin-10, respectively; AD = Alzheimer\'s disease; CI = confidence interval; G+ and T+ group the genotypes, GA+GG and CT+TT, respectively; *APOE*ε4 = apolipoprotein E ε4.

\*All analyses controlled for centre, age, gender and *APOE*ε4 genotype.

There was significant heterogeneity between the centres, and the interaction was only significant in one of the seven centres, Rotterdam, with an *SF*of 3.0 (95% confidence interval = 1.6--5.8, *p*= 0.0007). But the power to detect an *SF*of 1.6 was low in each centre, ranging from below 10% to 40%. The results for North Europe (*SF*= 1.7, *p*= 0.03) and for North Spain (*SF*= 2.0, p = 0.09) were consistent (Table [5](#T5){ref-type="table"}).

###### 

Interaction between *IL6*rs2069837 AA vs G+ and *IL10*rs1800871 CC vs T+, by region

  Region            Power\*   Adjusted^†^synergy factor (95% CI, *p*) in the risk of AD
  ----------------- --------- -----------------------------------------------------------
  North Europe^‡^   64%       **1.7 (1.05--2.6, 0.03)**
  North Spain^‡^    37%       2.0 (0.9--4.4, 0.09)
  All               76%       **1.6 (1.1--2.4, 0.01)**

*IL6*and *IL10*= the genes for interleukin-6 and interleukin-10, respectively; G+ and T+ group the genotypes, GA+GG and CT+TT, respectively; CI = confidence interval; AD = Alzheimer\'s disease; *APOE*ε4 = apolipoprotein E ε4.

\*To detect a synergy factor of 1.6 (as in the overall dataset) at 0.05.

^†^All analyses controlled for centre, age, gender and *APOE*ε4 genotype.

^‡^North Europe = Rotterdam, Bonn, OPTIMA, Nottingham and Bristol; North Spain = Santander and Oviedo.

Results were similar for men as for women (data not shown). The interaction was slightly stronger in older subjects: *SF*for \> 75 years = 1.71 (1.05--2.78, 0.03); *SF*for \< 75 years = 1.27 (0.56--2.87, 0.57). However, there was no 3-way interaction with age. Nor did we find a significant interaction with *APOE*ε4.

Discussion
==========

In our whole dataset of over 7,500 samples, we have replicated both the interaction reported by Infante et al 2004 \[[@B8]\] and also that found in our preliminary study in the Rotterdam dataset, between SNPs of *IL6*and *IL10*(Table [3](#T3){ref-type="table"}). Both interactions gave significant *SF*s of approximately 1.6. There was significant heterogeneity between centres, which was unsurprising since only two, Rotterdam and Santander, had \> 20% power to detect these interactions. But the results for the two main regions, North Europe and North Spain, were consistent (Table [5](#T5){ref-type="table"}). We conclude that this is likely to be a true effect, but not a very strong one. As in any example of true epistasis, the presence or absence of one factor critically influenced the effect of the other (Table [4](#T4){ref-type="table"}).

Further replication will require a dataset at least as large, with appropriate statistical control for differences between individual sample-sets. Underpowered studies are unhelpful, since chance can produce misleading results in such cases. This criticism may apply to a previous study of this interaction that had power of \< 2% to detect it. Even the large Rotterdam Study, with 395 cases of AD and 5,111 controls, only had 40% power to detect this interaction. Thus, further replication may require a meta-analysis.

IL-6 in age-related decline and in AD
-------------------------------------

There is much evidence that chronic, low-grade overexpression of IL-6 contributes to age-related decline. Blood levels of IL-6 can rise with age in humans \[[@B22]-[@B24]\]. Raised levels are associated with various age-related conditions, including risk of cognitive decline in some studies \[[@B25],[@B26]\], but not in all \[[@B27]\]. Raised levels have been consistently associated with increased mortality in several large prospective studies \[[@B28]-[@B31]\]. Raised levels have also been associated with various conditions considered to be risk factors for dementia and/or AD: subclinical and clinical cardiovascular disease and the risk thereof \[[@B32]-[@B34]\], type 2 diabetes and its risk \[[@B35],[@B36]\], psychological stress \[[@B37]\] and the damage following stroke (IL-6 also increased in CSF) \[[@B38],[@B39]\].

Further, raised blood levels of IL-6 have often been associated with AD \[[@B40]-[@B42]\] and also with the risk of AD \[[@B43]\], although not in all studies \[[@B44],[@B45]\]. Post-mortem studies, although small, have generally reported increased IL-6 levels or changed IL-6 distribution in AD brain \[[@B46]-[@B49]\], with one exception \[[@B50]\]. IL-6 was found not only in plaques, but also around the bodies of isocortical neurones, only in AD \[[@B46]\]. This evidence and that above suggest that dysregulation of IL-6 contributes to the development of AD.

A potential interaction between *IL6* and *IL10*
------------------------------------------------

Both IL-6 and IL-10 are produced by activated microglia and astrocytes (reviewed in \[[@B3],[@B4]\]). However, in contrast to IL-6, IL-10 acts to limit inflammation in the brain. IL-10 inhibits the production of IL-6 \[[@B51],[@B52]\] and its receptor \[[@B53]\]. Thus, certain combinations of genetic variants of *IL6*and *IL10*, i.e. those associated with high production of IL-6 combined with those associated with low production of IL-10, may contribute to the dysregulation of inflammation. High heritability (\> 50%) has been reported for *in vitro*stimulated production of both IL-6 and IL-10 \[[@B54]\]. The functions of two of our studied SNPs, *IL6*intron 2 A/G and *IL10*3\' C/T have not yet been investigated. Thus we cannot rule out that they might have effects on transcription or post-transcriptional processing. Alternatively, they may be in linkage disequilibrium with other, functional variants. On the other hand, studies of *IL6*-174G/C \[[@B55],[@B56]\], of *IL10*-819C/T \[[@B57]\] and of *IL10*-1082G/A \[[@B58]-[@B60]\] have reported that these SNPs affect transcription or are in linkage disequilibrium with those that do. However, it may be premature to designate any particular alleles as high or low producers, since there have been contrasting results for the effects of *IL6*-174G/C and *IL10*-1082G/A on transcription, on *in vitro*stimulated production and on blood levels of the respective proteins. But most studies have associated the *IL10*-1082GG genotype at least with higher *in vitro*stimulated production of IL-10 \[[@B61]-[@B64]\], although not all, \[[@B65],[@B66]\] and results have varied with experimental conditions \[[@B64],[@B66]\]. It appears that several SNPs in the regulatory regions of each gene affect transcription in an interactive and tissue-specific manner \[[@B56]\]. Indeed, we note that in our dataset the 2-SNP combination of *IL10 -1082G+/-819CC* has a slightly stronger interaction with *IL6*than that of either SNP alone (data not shown).

Conclusion
==========

We conclude that an interaction between IL-6 and IL-10 is plausible; that dysregulation of the two genes contributes to chronic low-grade inflammation in some elderly people and thus to the risk of AD; and that certain combinations of genetic variants in the regulatory regions of the two genes are conducive to this dysregulation. But in view of the linkage disequilibrium in the region of each gene (Table [2](#T2){ref-type="table"}), we cannot conclude that we have yet found the true risk polymorphisms. However, we suggest that our results are consistent with the contribution of inflammation to the onset of AD.
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